FibroGen to Report First Quarter 2023 Financial Results
FibroGen, Inc. (NASDAQ: FGEN) will release its first quarter 2023 financial results on May 8, 2023, following the market's close. A conference call is scheduled for 5:00 PM ET on the same day to discuss the company's performance with investors. FibroGen specializes in biopharmaceuticals, focusing on developing innovative therapeutics, including Pamrevlumab for treating idiopathic pulmonary fibrosis and various cancers, and Roxadustat, which is approved for managing anemia due to chronic kidney disease. Roxadustat is currently in Phase 3 clinical trials for additional anemia indications. Interested parties can access the conference call through the company's Investor Relations page or via phone. A replay will be provided afterward.
- Pamrevlumab and Roxadustat are in advanced clinical development stages.
- Roxadustat is already approved in multiple regions, expanding market potential.
- New product candidates in the immuno-oncology space enhance growth prospects.
- None.
SAN FRANCISCO, April 24, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its first quarter 2023 financial results on Monday, May 8 after the market close. FibroGen will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company's corporate and financial performance.
Conference Call and Audio Webcast
Interested parties may access a live audio webcast of the conference call via the “Investor Relations” page of the Company’s website at www.fibrogen.com. To access the call by phone, please go to this link (registration link), and you will be provided with dial-in details. To avoid delays, we encourage participants to dial in to the conference call fifteen minutes ahead of the scheduled start time. A replay of the webcast will also be available for a limited time at the following link (webcast replay).
About FibroGen
FibroGen, Inc. is a biopharmaceutical company committed to discovering, developing, and commercializing a pipeline of first-in-class therapeutics. The Company applies its pioneering expertise in connective tissue growth factor (CTGF) biology and hypoxia-inducible factor (HIF) to advance innovative medicines for the treatment of unmet needs. Pamrevlumab, an anti-CTGF human monoclonal antibody, is in clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), locally advanced unresectable pancreatic cancer (LAPC), metastatic pancreatic cancer, and Duchenne muscular dystrophy (DMD). Roxadustat (爱瑞卓®, EVRENZO™) is currently approved in China, Europe, Japan, and numerous other countries for the treatment of anemia in CKD patients on dialysis and not on dialysis. Roxadustat is in Phase 3 clinical development in the U.S. and Europe for anemia associated with myelodysplastic syndromes (MDS), and in Phase 3 clinical development in China for the treatment of chemotherapy-induced anemia (CIA). FibroGen recently expanded its research and development portfolio to include product candidates in the immuno-oncology space. For more information, please visit www.fibrogen.com.
Contacts: FibroGen, Inc.
Investors:
Michael Tung, M.D.
Corporate Strategy / Investor Relations
mtung@fibrogen.com
Media:
Meichiel Jennifer Keenan
Investor Relations and Corporate Communications
mkeenan@fibrogen.com
FAQ
When will FibroGen announce its Q1 2023 financial results?
What time is the conference call scheduled for?
What are the main products under development for FibroGen?
Is Roxadustat approved in regions outside the U.S.?
Where can I access the FibroGen conference call?
